07:00 , Apr 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK); kruppel-like factor 2 (KLF2); kruppel-like factor 4 (KLF4; EZF)

Cardiovascular disease INDICATION: Cardiovascular Patient sample and mouse studies suggest inhibiting the MAP4K3- KLF2 / KLF4 pathway could help treat cerebral cavernous malformations (CCMs), which involve the formation of highly dilated blood vessels and symptoms...
07:00 , Oct 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Lupus MAP kinase kinase kinase kinase 3 (MAP4K3; GLK) Patient sample and mouse studies suggest inhibiting GLK could help treat autoimmune diseases such as...
07:00 , Jul 16, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3) Studies in cell culture suggest that enhancing MAP4K3 activity could help treat cancer. In healthy cells,...
07:00 , Jun 10, 2002 |  BioCentury  |  Politics, Policy & Law

Skladany in for Suydam

With little prospect for appointment of a permanent FDA commissioner until after the fall congressional elections, Acting FDA Commissioner Lester Crawford has been taking steps to emphasize that an acting commissioner can act. But last...